| Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation (NCT07753148) | Regeneron Pharmaceuticals | 2026-09-17 |
| Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis (NCT07759167) | Regeneron Pharmaceuticals | 2026-09-09 |
| Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers (NCT07493304) | Regeneron Pharmaceuticals | 2026-08-31 |
| A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma (NCT07567469) | Regeneron Pharmaceuticals | 2026-08-31 |
| Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) (NCT07697599) | Regeneron Pharmaceuticals | 2026-08-20 |
| A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy (NCT07710846) | Regeneron Pharmaceuticals | 2026-08-17 |
| A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread (NCT07543055) | Regeneron Pharmaceuticals | 2026-08-10 |
| A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy (NCT07675811) | Regeneron Pharmaceuticals | 2026-07-31 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation (NCT07626411) | Regeneron Pharmaceuticals | 2026-07-31 |
| A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) (NCT07559513) | Regeneron Pharmaceuticals | 2026-07-30 |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes (NCT07685808) | Regeneron Pharmaceuticals | 2026-07-29 |
| REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension (NCT07675824) | Regeneron Pharmaceuticals | 2026-07-23 |
| REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma (NCT07594106) | Regeneron Pharmaceuticals | 2026-07-20 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) (NCT07609940) | Regeneron Pharmaceuticals | 2026-07-15 |
| Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) (NCT07631637) | Regeneron Pharmaceuticals | 2026-07-15 |
| Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease (NCT07318610) | Regeneron Pharmaceuticals | 2026-07-10 |
| This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization (NCT07587658) | Regeneron Pharmaceuticals | 2026-06-30 |
| Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity (NCT07594093) | Regeneron Pharmaceuticals | 2026-06-29 |
| A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia (NCT07477704) | Regeneron Pharmaceuticals | 2026-06-17 |
| A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently (NCT07154745) | Regeneron Pharmaceuticals | 2026-06-11 |
| A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) (NCT07428369) | Regeneron Pharmaceuticals | 2026-06-05 |
| First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis (NCT07527923) | Regeneron Pharmaceuticals | 2026-05-22 |
| A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD (NCT07527910) | Regeneron Pharmaceuticals | 2026-05-22 |
| A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) (NCT07393282) | Regeneron Pharmaceuticals | 2026-05-21 |
| A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults (NCT07526116) | Regeneron Pharmaceuticals | 2026-05-07 |
| Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) (NCT07318597) | Regeneron Pharmaceuticals | 2026-05-06 |
| A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06769698) | Regeneron Pharmaceuticals | 2026-04-14 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (NCT07430956) | Regeneron Pharmaceuticals | 2026-04-03 |
| A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma (NCT07455851) | Regeneron Pharmaceuticals | 2026-03-26 |
| A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease (NCT07142343) | Regeneron Pharmaceuticals | 2026-03-19 |
| A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT07154290) | Regeneron Pharmaceuticals | 2026-03-18 |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US (NCT07431086) | Regeneron Pharmaceuticals | 2026-03-16 |
| Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy (NCT07220785) | Regeneron Pharmaceuticals | 2026-03-13 |
| A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea (NCT07235917) | Regeneron Pharmaceuticals | 2026-03-11 |
| REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis (NCT07410117) | Regeneron Pharmaceuticals | 2026-03-09 |
| A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor (NCT07187401) | Regeneron Pharmaceuticals | 2026-02-11 |
| A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults (NCT07220772) | Regeneron Pharmaceuticals | 2026-02-09 |
| Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants (NCT07230834) | Regeneron Pharmaceuticals | 2026-01-19 |
| Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy (NCT07309432) | Regeneron Pharmaceuticals | 2026-01-10 |
| Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease (NCT07271186) | Regeneron Pharmaceuticals | 2026-01-09 |
| A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT07222761) | Regeneron Pharmaceuticals | 2026-01-02 |
| Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis (NCT06975787) | Regeneron Pharmaceuticals | 2025-12-22 |
| A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants (NCT07218770) | Regeneron Pharmaceuticals | 2025-12-17 |
| First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) (NCT07216066) | Regeneron Pharmaceuticals | 2025-12-05 |
| REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants (NCT07213778) | Regeneron Pharmaceuticals | 2025-11-24 |
| Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab (NCT07187089) | Regeneron Pharmaceuticals | 2025-11-11 |
| A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis (NCT07112378) | Regeneron Pharmaceuticals | 2025-11-10 |
| A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells (NCT06798298) | Regeneron Pharmaceuticals | 2025-11-10 |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation (NCT07175428) | Regeneron Pharmaceuticals | 2025-10-20 |
| Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study (NCT07105228) | Regeneron Pharmaceuticals | 2025-07-15 |
| A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US) (NCT06769412) | Regeneron Pharmaceuticals | 2025-07-01 |
| A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations (NCT06019481) | Regeneron Pharmaceuticals | 2025-06-30 |
| REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults (NCT07015905) | Regeneron Pharmaceuticals | 2025-06-25 |
| Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women (NCT06970405) | Regeneron Pharmaceuticals | 2025-05-29 |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer (NCT06787612) | Regeneron Pharmaceuticals | 2025-05-28 |
| A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension (NCT06608901) | Regeneron Pharmaceuticals | 2025-05-05 |
| A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) (NCT06836609) | Regeneron Pharmaceuticals | 2025-04-28 |
| REGN5381 in Adult Participants With Uncontrolled Hypertension (NCT06833190) | Regeneron Pharmaceuticals | 2025-04-16 |
| A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment (NCT06848088) | Regeneron Pharmaceuticals | 2025-04-14 |
| Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults (NCT06669234) | Regeneron Pharmaceuticals | 2025-03-06 |
| Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults (NCT06665828) | Regeneron Pharmaceuticals | 2025-03-04 |
| ALN-APOC3 in Adult Participants With Dyslipidemia (NCT06784349) | Regeneron Pharmaceuticals | 2025-01-27 |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma (NCT06585410) | Regeneron Pharmaceuticals | 2025-01-02 |
| A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) (NCT06548100) | Regeneron Pharmaceuticals | 2024-12-16 |
| An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (NCT06398080) | Regeneron Pharmaceuticals | 2024-12-12 |
| A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma (NCT06669247) | Regeneron Pharmaceuticals | 2024-12-11 |
| A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care (NCT06693531) | Regeneron Pharmaceuticals | 2024-11-22 |
| A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy (NCT06602739) | Regeneron Pharmaceuticals | 2024-11-19 |
| A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) (NCT06465329) | Regeneron Pharmaceuticals | 2024-11-18 |
| Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) (NCT06384820) | Regeneron Pharmaceuticals | 2024-11-14 |
| Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) (NCT06593600) | Regeneron Pharmaceuticals | 2024-11-13 |
| A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy (NCT06602726) | Regeneron Pharmaceuticals | 2024-11-06 |
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy (NCT06541704) | Regeneron Pharmaceuticals | 2024-10-30 |
| A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body (NCT06421636) | Regeneron Pharmaceuticals | 2024-09-30 |
| A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body (NCT06413680) | Regeneron Pharmaceuticals | 2024-09-23 |
| A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (NCT06299111) | Regeneron Pharmaceuticals | 2024-09-20 |
| A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma (NCT06190951) | Regeneron Pharmaceuticals | 2024-09-18 |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma (NCT06140524) | Regeneron Pharmaceuticals | 2024-09-16 |
| A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B (NCT06379789) | Regeneron Pharmaceuticals | 2024-09-11 |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) (NCT06246916) | Regeneron Pharmaceuticals | 2024-09-09 |
| First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) (NCT06351592) | Regeneron Pharmaceuticals | 2024-08-28 |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (NCT06572228) | Regeneron Pharmaceuticals | 2024-08-26 |
| A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (NCT06292780) | Regeneron Pharmaceuticals | 2024-08-07 |
| A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers (NCT06469281) | Regeneron Pharmaceuticals | 2024-08-06 |
| A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (NCT06491914) | Regeneron Pharmaceuticals | 2024-07-24 |
| A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery (NCT06161441) | Regeneron Pharmaceuticals | 2024-07-16 |
| A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (NCT06454630) | Regeneron Pharmaceuticals | 2024-06-27 |
| A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor (NCT06024408) | Regeneron Pharmaceuticals | 2024-05-21 |
| Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy (NCT06369467) | Regeneron Pharmaceuticals | 2024-05-17 |
| REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction (NCT06237309) | Regeneron Pharmaceuticals | 2024-04-11 |
| Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients (NCT06269133) | Regeneron Pharmaceuticals | 2024-02-21 |
| A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (NCT06230224) | Regeneron Pharmaceuticals | 2024-02-15 |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma (NCT05955508) | Regeneron Pharmaceuticals | 2024-01-30 |
| A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy (NCT05568459) | Regeneron Pharmaceuticals | 2024-01-17 |
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma (NCT06149286) | Regeneron Pharmaceuticals | 2023-12-28 |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (NCT05828511) | Regeneron Pharmaceuticals | 2023-12-19 |
| A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma (NCT06091865) | Regeneron Pharmaceuticals | 2023-12-13 |
| A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma (NCT06091254) | Regeneron Pharmaceuticals | 2023-12-12 |
| A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants (NCT06137482) | Regeneron Pharmaceuticals | 2023-12-06 |
| A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults (NCT05923424) | Regeneron Pharmaceuticals | 2023-11-28 |